Dilated Cardiomyopathy, Heart Failure With Reduced Ejection Fraction (HFrEF)
Conditions
Keywords
Heart Failure, Reduced Ejection Fraction, Cardiomyopathy
Brief summary
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Detailed description
The CORCINCH-HF Study is a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation of the AccuCinch Ventricular Restoration System. Subjects will be randomized in a 1:1 ratio: 1. Treatment group: AccuCinch Ventricular Restoration System plus guideline-directed medical therapy (GDMT) (n\ 200) 2. Control group: Guideline-directed medical therapy (GDMT) (n\ 200)
Interventions
DEVICEAccuCinch Ventricular Restoration System
AccuCinch Ventricular Restoration System
Guideline-Directed Medical Therapy
Sponsors
Ancora Heart, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18-years or older 2. Ejection Fraction: ≥20% and ≤40% measured by transthoracic echocardiography (TTE) and assessed by an echocardiography (echo) core lab 3. LV end-diastolic diameter ≥55 mm measured by TTE and assessed by an echo core lab 4. Symptom Status: 1. NYHA III, 2. NYHA ambulatory IV, or 3. NYHA II with a heart failure hospitalization within the prior 12 months (of signing the consent) 5. Able to complete six-minute walk test with distance between 100 m and 450 m. 6. Diagnosis and treatment for heart failure should be established at least 90 days before the date of consent. Subjects should be on stable, optimally titrated medical therapy for at least 30 days, as recommended according to current guidelines as standard-of-care for Heart Failure therapy, with any intolerance documented. 1. "Stable" is defined as no more than a 100% increase or a 50% decrease of total daily doses. Medication changes within this range do not require any additional waiting before the screening assessments 2. When a total daily dose increase or decrease exceeds that which is considered stable, the screening TTE and CT will be postponed 30 days after the medication change 3. When additional titration is required to optimize a subject's medication that exceeds what is considered stable, the screening TTE and CT will be postponed at least 30 days after achieving the optimal dose (provided the optimal dose remains outside of the stable parameters) 4. When a dose-for-dose equivalent change in the class of medication change is made, no additional waiting is required before the screening assessments 5. When a change in class medication change exceeds what is considered stable, OR a new class of medication is added, the screening TTE and CT will be postponed 30 days after the medication change 6. If an SGLT2 inhibitor is added to a subject's medications, the screening TTE and CT will be postponed at least 30 days after the addition 7. If an SGLT2 inhibitor dose changes per the stable definition above, no additional waiting is required before the screening assessments 8. If an SGLT2 inhibitor dose change exceeds what is considered stable, the screening TTE and CT will be postponed at least 30 days after achieving the optimal dose (provided the dose remains outside of the stable parameters) 9. When applicable, for guideline-directed device-based therapies: a CRT device must be placed \> 90 days before the screening TTE and CT, and an ICD must be placed \> 30 days before the screening TTE and CT 7. Able and willing to complete all qualifying diagnostic and functional tests, willing to accept blood product transfusion if required and agrees to comply with study follow-up schedule
Exclusion criteria
Cardiovascular 1. Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 90 days prior to consent 2. Untreated clinically significant coronary artery disease (CAD) requiring revascularization 3. Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation 4. Suboptimal ventricular anatomy or wall thickness as determined from screening echocardiography and/or CT scan 5. Heart failure on the basis other than ischemic or non-ischemic dilated cardiomyopathy (e.g., hypertrophic cardiomyopathy, amyloid cardiomyopathy, restrictive cardiomyopathy, uncorrected congenital heart disease, constrictive pericarditis) 6. Hemodynamic instability within 30 days prior to the implant defined as subject requiring inotropic support or mechanical hemodynamic support 7. Any planned cardiac surgery or interventions within the next 180 days post-randomization (including therapeutic right heart procedures) 8. Active bacterial endocarditis 9. Severe RV dysfunction assessed by right heart catheterization (RHC) and/or TTE 10. Fixed pulmonary hypertension with PA systolic pressure \>70 mmHg not responsive to vasodilator therapy 11. History of any stroke within the prior 90 days of consent or documented Modified Rankin Scale ≥ 2 disability from any prior stroke Valvular 12. Mitral regurgitation grade 3+ (moderate-severe) or 4+ (severe) 13. Untreated degenerative (primary) mitral valve disease (mild prolapse with no need for intervention is allowable) 14. Prior mitral or aortic valve replacement 15. Tricuspid regurgitation grade 4+ (severe) 16. Moderate or severe aortic valve stenosis (AVA less than 1.5 cm2 or peak velocity AV Vmax \>300 cm/sec) 17. Aortic regurgitation grade 2+ (moderate), 3+ (moderate-severe), or 4+ (severe) Procedural 18. Anatomical pathology or constraints preventing appropriate access/implant of the AccuCinch Ventricular Restoration System (e.g., femoral arteries will not support a 20F Introducer sheath) 19. Renal insufficiency (i.e., eGFR of \<25 ml/min/1.73 m2) 20. Subjects in whom anticoagulation during the procedure is contraindicated 21. Subjects in whom 90 days of antiplatelet therapy is contraindicated 22. Known allergy to nitinol, polyester, or polyethylene 23. Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure General 24. Life expectancy \<1 year due to non-cardiac conditions 25. Currently participating in another interventional investigational study 26. Subjects on high dose steroids or immunosuppressant therapy 27. Female subjects who are pregnant, of child-bearing potential without a documented birth control method, or who are lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from device- or femoral artery access-related major adverse events (MAE) | 180 days | MAE defined as: 1. All-cause death, 2. Myocardial infarction, 3. Stroke, 4. Need for non-elective cardiovascular surgery, 5. Worsening of heart-failure requiring mechanical circulatory support for more than 24 hours 6. Acute kidney injury requiring renal replacement therapy |
| Change from baseline in Kansas City Cardiomyopathy Questionnaire Quality of Life Questionnaire (KCCQ) Score | 180 days | Higher scores in the KCCQ reflect better health status |
| 6-Minute Walk Test (6MWT) distance (m) | 180 days | Change in 6MWT distance (m) from baseline |
| A hierarchical composite endpoint of all-cause deaths, left ventricular assist device (LVAD) implants or heart transplants, heart failure hospitalizations, and changes from baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) | 365 days | A hierarchical composite endpoint of number of all-cause deaths, number of left ventricular assist device (LVAD) implants or heart transplants, number of heart failure hospitalizations, and change from baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS), evaluated using the Win Ratio method |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of all-cause deaths or all-cause hospitalizations | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Number of all-cause deaths | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Number of all-cause hospitalizations | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Incidence of all serious adverse events, including device- and procedure- related complications | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Changes from baseline in New York Heart Association (NYHA) functional class | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Changes from baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) | 30 days, 90 days, 365 days, 545 days, 730 days | Higher scores in the KCCQ reflect better health status |
| Changes from baseline in 6-Minute Walk Test (6MWT) | 30 days, 90 days, 365 days, 545 days, 730 days | Measure in meters |
| Changes in left ventricular ejection fraction (LVEF) from baseline and from post-procedure/pre-hospital discharge as assessed by echo | 30 days, 90 days, 365 days, 730 days | — |
| Changes in left ventricular ejection fraction (LVEF) from baseline and from post-procedure/pre-hospital discharge as assessed by echo and CT | 180 days | — |
| Changes in left ventricular end-diastolic volume (LVEDV) from baseline and from post-procedure/pre-hospital discharge as assessed by echo | 30 days, 90 days, 365 days, 730 days | — |
| Changes in left ventricular end-diastolic volume (LVEDV) from baseline and from post-procedure/pre-hospital discharge as assessed by echo and CT | 180 days | — |
| Changes in left ventricular end-systolic volume (LVESV) from baseline and from post-procedure/pre-hospital discharge as assessed by echo | 30 days, 90 days, 365 days, 730 days | — |
| Changes in left ventricular end-systolic volume (LVESV) from baseline and from post-procedure/pre-hospital discharge as assessed by echo and CT | 180 days | — |
| Rate and number of cardiovascular death events | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Rate and number of heart failure death events | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
| Rate and number of heart failure-related hospitalizations | 30 days, 90 days, 180 days, 365 days, 545 days, 730 days | — |
Countries
Belarus, Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Serbia, United States
Contacts
STUDY_CHAIRMartin B Leon, MD
Columbia University
PRINCIPAL_INVESTIGATORUlrich P Jorde, MD
Montefiore Medical Center/Albert Einstein College of Medicine
PRINCIPAL_INVESTIGATORShmuel Chen, MD
New York Presbyterian/Weill Cornell Medicine
Outcome results
None listed